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Abstract
Background: Clinical care for older adults is complex and represents a growing problem. They are a diverse patient
group with varying needs, frequent presence of multiple comorbidities, and are more susceptible to treatment
harms. Thus Clinical Practice Guidelines (CPGs) need to carefully consider older adults in order to guide clinicians.
We reviewed CPG recommendations for primary cardiovascular disease (CVD) prevention and examined the extent
to which CPGs address issues important for older people identified in the literature.
Methods: We searched: 1) two systematic reviews on CPGs for CVD prevention and 2) the National CPG
Clearinghouse, G-I-N International CPG Library and Trip databases for CPGs for CVD prevention, hypertension and
cholesterol. We conducted our search between April and December 2013. We excluded CPGs for diabetes, chronic
kidney disease, HIV, lifestyle, general screening/prevention, and pregnant or pediatric populations. Three authors
independently screened citations for inclusion and extracted data. The primary outcomes were presence and extent
of recommendations for older people including discussion of: (1) available evidence, (2) barriers to implementation
of the CPG, and (3) tailoring management for this group.
Results: We found 47 eligible CPGs. There was no mention of older people in 4 (9 %) of the CPGs. Benefits were
discussed more frequently than harms. Twenty-three CPGs (49 %) discussed evidence about potential benefits and
18 (38 %) discussed potential harms of CVD prevention in older people. Most CPGs addressed one or more barriers
to implementation, often as a short statement. Although 27 CPGs (58 %) mentioned tailoring management to the
older patient context (e.g. comorbidities), concrete guidance was rare.
Conclusion: Although most CVD prevention CPGs mention the older population to some extent, the information
provided is vague and very limited. Older adults represent a growing proportion of the population. Guideline
developers must ensure they consider older patients’ needs and provide appropriate advice to clinicians in order to
support high quality care for this group. CPGs should at a minimum address the available evidence about CVD
prevention for older people, and acknowledge the importance of patient involvement.
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Background
Available evidence for older people
It is a major challenge for clinicians to provide appropri-
ate and patient centered care for older people with co-
morbidities. Clinical practice guidelines (CPGs) aim to
support clinician decision making, however, CPGs may
not always be straight forward to implement for older
people for several reasons [1]. Older people have gener-
ally been excluded from clinical trials, and when in-
cluded they are generally more fit and healthy than the
older people in the community [2, 3]. Furthermore, clin-
ical trials often do not address outcomes that may have
high priority for older adults (e.g. quality of life and in-
dependent living) [4]. Moreover, most CPGs focus on a
single disease, however the prevalence of comorbidities
increases with age and studies in Australia [5] and
Scotland [6] estimate that around 70 percent of people
over 75 have two or more chronic conditions. Applying
CPGs for each condition leads to polypharmacy, in-
creases treatment burden, and risk of adverse events [1].
Barriers to implementation of CPGs
There are other barriers to applying CPGs to older people.
Treatment in older populations is generally more complex
due to comorbidities and associated polypharmacy. Data
from the US and Australia suggest that over 90 % of older
persons (75 years and above) take one or more prescrip-
tion medication, with approximately 40 % of older persons
using five or more prescription medications at one time
[7, 8]. Older people who take multiple medications are at
increased risk of experiencing adverse drug reactions [9]
and the presence of comorbidities and polypharmacy also
means that it can be difficult to predict the effect of a
treatment, and compare the overall benefits and harms
[10]. Moreover, older people are heterogeneous in terms
of general health status, frailty and cognitive function and
even older people with the same diagnosis may therefore
respond different to treatment [4]. Older people will also
vary in terms of prognosis, and when applying CPG rec-
ommendations to older people it is important to deter-
mine if the person is likely to benefit from the medication
within their remaining life (time needed to treat to bene-
fit) [11, 12]. Moreover, they will vary in their treatment-
and health outcome preferences (e.g. length of life versus
quality of life, physical and cognitive functioning, risk re-
duction, tolerance of side effects) [13–15].
Tailoring treatment to older patient context, preferences
and goals
Decision making about initiating treatment in older
people therefore requires careful tailoring to the individ-
ual patient’s circumstances and it is critical to involve
the older patient and take their preferences into account
in the shared decision. Older patients’ preferences and
treatment goals are are more variable than younger
people, and likely to change depending on factors such as
health and mood [15, 16]. This highlights the importance
of eliciting patient preferences when deciding on treat-
ment in this group. Most people, including older people
[17], prefer to be involved in the decision making process.
The majority of older people want to discuss options and
receive information even though they may not wish to be
involved in making the final decision [18] and value the
input of their family member/carer who are often present
in the consultation [19]. However, CPGs are often not set
up in a way that optimally supports patient involvement
and shared decision making [20], this is a general limita-
tion although it is probably particularly relevant for older
people.
Need for guidance primary CVD prevention in older
people
In this paper we focus on CPGs for primary cardiovascular
disease (CVD) prevention in older people. Worldwide, the
population is aging and because CVD risk increases with age,
this creates a major public health burden.Moreover, medica-
tion use for CVD prevention is common in older people, for
example one-third of people aged 75–84 in Sweden [21] are
treated with statins and in the US over 80 % of adults with
hypertension aged 60 or older receive anti-hypertensive
medication [22]. This means that there is a clear imperative
for CPG for primary CVD prevention to address older
people. Most international cardiovascular disease (CVD) pri-
mary prevention CPGs encourage the use of 5- or 10 year ab-
solute (or overall, global or combined) CVD risk scores (AR)
to target preventive treatment in asymptomatic patients who
are at high risk [23]. However, CVD risk prediction models
are not well validated in older people, for example the widely
used Framingham risk equation is based on a patient cohort
with an upper age of 74 [24]. Because AR increases with age,
and people at higher risk benefit more in terms of risk reduc-
tion, it is reasonable to argue that older people (and especially
otherwise healthy older people) have the potential to benefit
at least as much from primary CVD prevention as younger
people [25, 26] and otherwise healthy older people should
not be denied potentially effective preventative medication
based on their age alone. However, although there is some
evidence of the benefits of blood pressure [27, 28] and chol-
esterol lowering medication in older people [29, 30], most of
these studies did not take into account comorbidities [31].
Also, the harms of medication (e.g. myopathy with choles-
terol medication and risk of falls with blood pressuremedica-
tion) are more likely to occur in older people [31–34] and
older people are likely to vary widely in the relative import-
ance they place on benefits and harms of CVD medication
[15]. Moreover, not every older patient will be able to achieve
benefits from long-term preventative CVD medication dur-
ing their remaining life span [12].
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In summary, when making decisions about primary
CVD prevention for older people, clinicians have the chal-
lenging task of weighing AR with life expectancy, co-
morbidities, the benefits and harms of medication, and
preferences of patients and family members/carers. Not
surprisingly, clinicians have reported the need for clearer
guidance in this area [35]. The purpose of this paper is to
systematically review international CPGs for primary CVD
prevention to examine the extent to which they address
older adults and take into account factors important for
patient-centered care of older people that we identified
from the literature [1, 4, 13, 36, 37] as described above:
available evidence for older people, barriers to implemen-
tation of the CPG for older people, and tailoring treatment
to older people context and preferences. Studies looking
at Australian and Canadian CPGs suggest that only a few
provide recommendations tailored to the special needs of
older people [36, 37]. As far as we are aware, no studies
have examined CPG recommendations for primary CVD
prevention in older people.
Methods
Data sources
First, we searched two systematic reviews on CPGs for
CVD prevention [23, 38] for CPGs discussing a combined,
overall, global, total or absolute risk approach (from here
on referred to as AR approach) and looked for updated
version of these CPGs. Second, we performed our own
systematic review to search for CPGs published after May
2009, the time-frame used in the previous studies, by
searching the following three CPG-specific databases: the
National CPG Clearinghouse (http://www.guideline.gov),
G-I-N International CPG Library (http://www.g-i-n.net)
and Trip database (https://www.tripdatabase.com). These
databases are publicly available on the Internet. We con-
ducted our search between April and December 2013.
Inclusion/exclusion criteria
We included published CPGs on the assessment and/or
management of CVD risk or two important risk factors
for CVD: hypertension and high cholesterol. We only
considered CPGs that mentioned an AR approach and
specifically aimed to prevent a first CVD event (primary
prevention). We excluded CPGs for diabetes, chronic
kidney disease, HIV, lifestyle, general screening/preven-
tion, pregnant or pediatric populations. We restricted
the search to English language CPGs. Where more than
one version of the same CPG was found we included
only the most recent version.
Search strategies
An information specialist was consulted to design the
search strategy. The Medline search strategy consisted of
two categories of subject headings (MESH) and title
words (intersected by the Boolean term “AND”) covering
(1) CVD, hypertension and dyslipidemia: (cardiovascular
disease, heart disease, vascular disease, cardiac, coronary,
ischemic, cardiovascular, cerebrovascular disorders, stroke,
peripheral vascular diseases, renovascular or stroke, dys-
lipidemia, cholesterol, lipid, hypertension, blood pressure);
and (2) clinical practice guidelines (practice guidelines,
guidelines, clinical or practice and guidelines). We limited
our search to English language articles. The Medline
search syntax served as a basis for all search strategies.
The full search strategy is available on request from the
authors. We were also provided with CPGs through infor-
mal communication.
Two reviewers (JJ and SM) independently assessed all
1) titles and 2) abstracts/full text CPGs for potential eli-
gibility, with discrepancies resolved by consensus if
needed after discussion with all authors (see Fig. 1). For
CPGs extracted from the two existing reviews, we com-
bined step 1 and 2.
Outcomes
When no specific age cut-off for older adults was indi-
cated in the CPG, we looked for words that signified
older age (e.g., senior, frail, elderly). The primary out-
come was to identify the extent to which recommenda-
tions for CVD assessment/management in older adults
(with or without comorbidities ) were given, more spe-
cifically any mention of: (1) available evidence for older
people, (2) barriers to implementation of the CPG for
older people, and (3) tailoring treatment to older people
context and preferences. These criteria were selected
from literature on the applicability of CPGs and patient
centered care for older people [1, 4, 13, 36, 37]. See
Table 1 for a more detailed description of these criter-
ia.We only included statements that explicitly referred to
older patients, which means that general statements for
example about the importance of patient involvement
are not reported. Data were collected, summarized, and
tabulated in an Excel spread sheet.
Data collection and analysis
An initial data extraction plan was formulated (JJ), then
discussed and revised with additional categories (JJ, CB,
KM, SM), before all authors agreed on the approach.
Three authors (JJ, SM, BN) independently extracted data
from included CPGs and all CPGs were double coded to
ensure accuracy and consistency. Any discrepancies were
resolved by consensus to establish a single dataset. Data
was collected on year of publication/update, principal
disease, organization responsible for CPG development,
country/region, whether it was an assessment CPG, a man-
agement CPG, or both. In line with the outcome measures,
information was also extracted on any statements/recom-
mendations that specifically addressed older people.
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Results
Of 1035 screened abstracts and 301 full text CPGs, 47
CPGs were included: 23 on assessment/management of
CVD risk in general, 13 on cholesterol, and 11 on hyper-
tension. Additional file 1: Appendix A summarizes the
selected CPGs, including risk model and condition:
CVD, hypertension or cholesterol. The denominator
used is all CPGs (n = 47) unless statements specifically
relate to hypertension or cholesterol (medication); in
those instances the denominators are 34 (23 CVD + 11
hypertension CPGs) and 36 (23 CVD + 13 cholesterol
CPGs), respectively.
Inclusion of information related to older people
Almost all CPGs (92 %, 43/47) specified an age range
for the target population and/or provided specific
recommendations for older people. The statements
provided ranged from general and brief to extensive
and more specific recommendations providing refer-
ences to relevant evidence, although the latter was rare (see
Additional file 2: Appendix B). Thirty-eight percent of the
CPGs (18/47) addressed older people with comorbidities,
mostly just briefly mentioning that CVD risk management
in older people should take into account comorbidities
without specifying specific co-occurring conditions. In
addition, 21 % (10/47) of the CPGs referred to frail older
people, mostly recommending more caution with man-
aging CVD risk in this group. Not in Table/Figure.
“People aged 75 or older should be considered at
increased risk of CVD (…). Assessment and treatment
should be guided by the benefits and risks of
Fig. 1 Summary of CPG search and review process
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treatment, informed preference and comorbidities that
may make treatment inappropriate [39]”.
“Initial doses and subsequent dose titration should be
more gradual because of a greater chance of
undesirable effects, especially in very old and frail
subjects [40]”.
Available evidence for older people
In total, 55 % (26/47) of the CPGs discussed the available
evidence for primary CVD prevention in older people (see
Fig. 2 for more detail). There was a disparity between
discussion of potential benefits and harms, with benefits
discussed more frequently (49 % of the CPGs, 23/47), than
harms (38 % of the CPGs, 18/47). Knowledge gaps were
discussed in 36 % of the CPGs (17/47). Additional file 2:
Appendix B describes examples of brief and more exten-
sive guideline recommendations for older people according
to the three criteria for CPG recommendations in older
people and Table 2 lists potential benefits and harms of dif-
ferent CVD risk management strategies (primary preven-
tion) as mentioned in the CPGs.
Potential benefits
Nineteen percent (9/47) of the CPGs discussed overall
benefits of CVD assessment and management in older
people, mostly referring to a similar relative benefit but
greater absolute benefit for older people due to higher
pre-treatment risk. Benefits of medication (morbidity/
mortality benefit, positive effects on cognition) were dis-
cussed in 32 % (11/34) of the CVD/hypertension CPGs
and 33 % percent (12/36) of the CVD/cholesterol CPGs.
Fifteen percent of all CPGs (7/47) discussed the benefits
of lifestyle management on CVD related morbidity and
mortality.
Potential harms
Overall harms of CVD risk assessment and management
in older people were discussed in 17 % (8/47) of the
CPGs, mainly addressing that absolute risk assessment
may underestimate risk in older people, and the use of
resources for older people who are less likely to benefit
due to short lifespan. Nineteen percent (7/36) of CVD/
cholesterol CPGs mentioned potential harms of choles-
terol lowering medication (e.g. muscle toxicity, increased
risk of cancer) whereas only 15 % (5/34) of CVD/hyper-
tension CPGs mentioned potential harms of blood pres-
sure medication, mostly referring to risk of hypotension.
None of the CPGs mentioned potential harms of lifestyle
change in older people.
Benefit harm trade-off
Generally, the trade-off between benefits and harms of
medication is more complicated in older people. Twenty-
five percent (13/47) of the CPGs explicitly referred to mak-
ing this trade-off, with statements varying from very
general statements to more extensive discussions in a few
cases (see for example New Zealand Primary Care Hand-
book 2012 in Additional file 2: Appendix B).
Knowledge gaps
Knowledge gaps related to CVD risk assessment and man-
agement in older people were discussed in 15 % (7/47) of
the CPGs, describing that most CVD risk models and in-
terventions have not been thoroughly tested in older
people, and the lack of generalizability of randomized clin-
ical trials to older people in the community. Seventeen per-
cent of the CVD/cholesterol CPGs (6/36), and 12 % of the
CVD/hypertension CPGs (4/34) addressed limited available
evidence of treatment with preventative CVD medication
for older people, especially the very old/more frail. None of
Table 1 Overview of criteria for CPG recommendations for older people*
Inclusion of information related to:
1. Available evidence primary CVD prevention
for older people
2. Barriers to implementation of the CPG
for older people
3. Tailoring treatment to older people context and
preferences
a. Evidence potential benefits/harms a. Risk assessment complexity (e.g. measurement
issues)
a. Patient preferences/values
b. Knowledge gaps
b. Risk management complexity (e.g. feasibility
treatment targets)
b. Family preferences/values
c. Time needed to treat to benefit in context of
life expectancy
c. Patient context (e.g. quality of life, life
expectancy, comorbidities)
d. Meaningfulness outcomes for older people
d. Weighing benefits/harms
e. Treatment adherence issues
e. Therapy prioritization
f. Cognitive status
g. Social support/caregiver burden
*Criteria were selected from literature on the applicability of CPGs and patient centered care for older people [1, 4, 13, 34, 35]
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the CPGs addressed knowledge gaps around lifestyle inter-
ventions for older people.
Aspirin in CVD CPGs
Despite the lack of evidence for the use of aspirin in pri-
mary prevention of CVD [41], 9 % (4/47) of the CPGs
mentioned the potential benefits in terms of CVD mor-
bidity/mortality and specifically reduction of myocardial
infarctions. Most of these CPGs (6 %, 3/47) also
addressed the increased risk of gastrointestinal bleeds
and/or hemorrhagic strokes and suggested that older
people need higher baseline risk for benefits to outweigh
harms (not in Figure/Table).
Barriers to implementation of the CPG for older people
The majority of CPGs addressed one or more barriers to
application of the guideline in older people (83 %, 39/
47). Details of the specific barriers or complexities that
Fig. 2 Available evidence different CVD risk management strategies (primary prevention) as mentioned in the CPGs (n = 47). Legend: *No harms
or knowledge gaps mentioned for lifestyle. Abbreviations: assess/mgt = assessment/management, BP = blood pressure, meds =medication,
chol = cholesterol
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Table 2 Potential benefits, harms and knowledge gaps of different CVD risk management strategies (primary prevention) for older
people as mentioned in the CPGs (n = 47)
Potential benefits Potential harms Knowledge gaps
CVD risk assessment Provides an estimate of CVD* risk in
older people
Risk models underestimate CVD risk
for older people
Risk models not rigorously tested/
reliable in older people
Disagreement about the efficacy of
risk assessment in older people (75+)
Most CVD risk models focus on short
term risk, and are therefore inevitably
more likely to classify older people as at
high risk and the young as at low risk
Beneficial in older patients with multiple
risk factors and good quality of life
Repeated screening of cholesterol is
less important as lipid levels are less
likely to increase after age 65 Older people could be considered at
high CVD risk based on their age while
other risk factors are relatively low
Disease labeling healthy older people
CVD risk management
overall
CVD risk reduction Risk of adverse effects is higher in
older people
Limited available evidence for older
people esp. older people with
comorbidities and ‘oldest of old’
(age definitions are variable)
Part of lifetime approach to CVD
prevention Resources are likely to be concentrated
on older people, who may not be able
to benefit in their remaining life (time
needed to treat to benefit)
Similar relative benefit but greater
absolute benefit for older people due
to higher pre-treatment risk
Lack of generalizability of RCTs† to
older people in the community
Similar benefit in old people as in young
people (when taking into account higher
case fatality rates after a CVD event in
older people and temporal discounting of
life years gained)
Disagreement about the efficacy of risk
management in older people (75+)
Costs associated with inappropriate
prescribing in older people
Implication of knowledge gaps is
that patient preferences and
potential harms must be taken into
account more, not just treatment
benefits
Improved quality of life
Both BP and cholesterol
medication
Morbidity/mortality benefit in older
people
Risk of adverse effects is higher in
older people, esp. frail and very old;
risk is acceptable as long as the
patient is carefully monitored
Limited available evidence for older
people esp. frail old and older
people with comorbidities; age
definitions are variableChoice of drug should not be age
dependent and is less important than
degree of BP/cholesterol reduction Lack of generalizability of RCTs to
older people in the community
Benefit for different treatment threshold/
dosages in older people provided
Benefits provided for specific drugs
Benefits provided for different older age
groups, age definitions are variable
Blood pressure medication No upper age limit to benefit Risk of diabetes onset with thiazide
diuretics
Limited available evidence on the
benefits/harms of lowering SBP§ below
certain threshold in older peoplePre-existing very high risk might set a
ceiling effect to the benefits of
treatment; incl. in older patients
Risk of postural hypotension
especially with alpha blockers Older people are under-represented in
trials vs. incentive to recruit more elderly
to get enough high risk patients and
CVD events for adequate power
Morbidity but not mortality benefit in
very old patients
Reducing BP‡ has benefits for other
conditions beyond CVD (cognitive
decline, dementia)
Unknown whether certain medication
classes are superior to others in
preventing cognitive decline
Cholesterol medication Stronger evidence for the benefits of
cholesterolmedication for secondary
prevention than primary prevention in
older people
Small increase in all-cause mortality in
older people
Association between high cholesterol
and mortality weaker in older people
Higher riskmuscle toxicity in older people
Frailty is an additional risk factor for
myopathy
Benefit for older people with risk
factors other than age
Increased risk of cancer in older people
Benefit continuing well tolerated
medication vs. starting medication
Very small risk of new-onsetdiabetes inolder
peoplebutdoesnotoutweighbenefit
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were mentioned are discussed below and Additional file 3:
Appendix C provides illustrative quotes from the CPGs.
Risk assessment complexity
Absolute CVD risk (AR) approach
Forty-nine percent (23/47) of the CPGs addressed the
complexities CVD risk assessment in older people
(Fig. 3). For AR assessment, some CPGs (6 %, 3/47) rec-
ommended a similar approach in younger versus older
people, whereas other CPGs (11 %, 5/47) advised to ex-
trapolate the risk model for older people outside the tar-
get age range, either by using the upper age cut-off of
the model or by providing adjusted risk scores for older
people. Eleven percent of the CPGs (5/47) stated that
older people above a certain age (usually > 80 years) or
older people with additional risk factors (e.g. hyperten-
sion, large pulse pressure, smokers, diabetes) can be as-
sumed to be at high risk without a formal assessment.
Blood pressure measurement
Thirty-five percent of the CVD/hypertension CPGs (12/
34) addressed blood pressure measurement in older
people, including recommendations to measure blood
pressure both lying/sitting and standing to document
postural hypotension, and information about the higher
predictive value of systolic blood pressure (SBP) versus
diastolic blood pressure (DBP) in determining CVD risk,
especially in older people.
Additional tests
Twenty-three percent (11/47) of the CPGs mentioned
the use of additional tests in the assessment and man-
agement of CVD risk in older people, including ankle-
brachial index (ABI), ultrasound, wave velocity and
echocardiography to detect possible arterial disease, cog-
nitive tests and MRI to detect silent brain infarcts and
Table 2 Potential benefits, harms and knowledge gaps of different CVD risk management strategies (primary prevention) for older
people as mentioned in the CPGs (n = 47) (Continued)
Lifestyle Benefit of healthy diet, physical activity,
smoking,moderate alcohol intake
Not discussed Not discussed
Benefits of physical activity in older people
includemortality benefit, improved quality
of life and CVD risk reduction.
Weight loss and reduction of salt intake
lowers blood pressure
Aspirin Reduced risk of CVD events/myocardial
infarctions but older people need to have
higher baseline risk for benefits to
outweigh harms
Risk of adverse effects increaseswith age
in particular gastrointestinal bleeding and
hemorrhagic strokes
Not discussed
*CVD: cardiovascular disease; †RCT: randomized controlled trial; ‡BP: blood pressure; §SBP: systolic blood pressure
Fig. 3 Barriers to implementation of the guideline for older people as mentioned in CPGs. Legend: Percentage of total number of guidelines
n = 47; *Calculated out of 34 (23 CVD + 11 hypertension) CPGs
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creatine kinase tests before initiating treatment with
cholesterol medication. This is despite the lack of good
evidence for the use of tests above the Framingham risk
equation.
Risk management complexity
Management in general
Sixty-six percent (31/47) of the CPGs addressed man-
agement of CVD risk in older people. Twenty-six per-
cent (12/46) stated that primary CVD prevention is
generally similar for older versus younger people. How-
ever, age-specific recommendations were also provided,
often by the same CPGs. Most commonly, CPGs pro-
vided a list of suitable and unsuitable pharmacotherapy
(38 %, 18/47) and lifestyle strategies (23 %, 11/47) for
older people. Thirteen percent (6/47) addressed side ef-
fects that are more likely in older people, most notably
increased risk of muscle toxicity with cholesterol lower-
ing medication. Common recommendations for older
people were to closely monitor side effects and adjust
medication dosage (15 %, 7/47) if need be.
Treatment targets
Treatment targets for older people were addressed in
19 % (9/47) of the CPGs. Some CPGs recommended
similar targets for younger and older people (9 %, 4/
47) whereas other CPGs commented that targets may
be difficult to achieve (9 %, 4/47) or recommended
specific, less stringent targets for older people (13 %,
6/47). For example, one CPG recommended a target
blood pressure below 150/90 mmHg in people aged
80 years and over versus 140/90 mmHg in younger
people [42]. None of the cholesterol CPGs discussed
treatment targets for older people.
Cognition and treatment adherence
Cognition in older people was addressed in in 13 % (6/
47) of CPGs, describing the relation between hyperten-
sion/high cholesterol and cognitive impairment (see ap-
plicability of evidence) or the relation between cognitive
function and adherence. Thirteen percent of the CPGs
(6/47) mentioned that treatment adherence is generally
lower in older people, especially in those with comorbid-
ities and cognitive/functional impairments. One CPG
recommended to improve adherence by simplifying the
medication regimen. None of the guidelines discussed
social support or caregiver burden.
Tailoring treatment to older people context and preferences
Patient context and preferences
More than half of the CPGs (58 %, 27/47) addressed older
patient context to some extent. Most commonly (32 %, 15/
47) CPGs recommended that the decision to assess and/or
manage CVD risk in older people should be based on clin-
ical judgment taking into account comorbidities/polyphar-
macy (38 %, 18/47), patient preferences (19 %, 9/47), life
expectancy and/or time needed to treat to benefit (19 %, 9/
47), and quality of life (11 %, 5/47). These factors were
often presented in list form, instructing clinicians to apply
the CPGs with consideration of individual patient context
but offering no specific guidance on how to do this. None
of the CPGs addressed preferences of family members/
companions (Fig. 4).
Weighing benefits/harms and therapy prioritization
Twenty-eight percent (13/47) of the CPGs mentioned
weighing up the benefits and harms of CVD prevention
for older people (see Table 2) and only one CPG expli-
citly mentioned the importance of prioritizing treatment
in older people, albeit as a side issue.
Fig. 4 Tailoring treatment to older people context and preferences as mentioned in CPGs. Legend: Percentage of total number of
guidelines n = 47
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Deprescribing
Discontinuation of medication in older people was not
considered in any of the CPGs, although one CPG expli-
citly mentioned that “(…) there is no reason for inter-
rupting a successful and well tolerated therapy when a
patient reaches 80 years of age [40].”
Discussion
Ninety-two percent of the included CPGs (43/47) referred
to older adults to some extent, but the specific issues im-
portant in deciding about primary cardiovascular disease
(CVD) prevention in older patients were mostly not ad-
equately addressed. There was very limited discussion of
frail older people and older people with comorbidities, a
group for whom management is particularly challenging
due to potential drug-drug and disease-drug interactions
and competing health priorities [10, 43]. Only 55 % of the
CPGs discussed available evidence for primary CVD pre-
vention in older people and knowledge gaps. Potential
benefits (in terms of morbidity, mortality and improved
cognition) were discussed more extensively than harms
(e.g. risk of hypotension with blood pressure medication),
especially for hypertension medication and lifestyle rec-
ommendations. This is an important finding as even
though older peoples’ preferences to take medication for
primary CVD prevention vary widely [15] they are rela-
tively insensitive to its benefit but highly sensitive to its
adverse effects [14, 44], suggesting that clinical CPGs need
to place emphasis on both benefits and harms, especially
for older people. More specific adverse effects were men-
tioned for cholesterol medication than blood pressure
medication, for example only a few CPGs mentioned an
increased risk of fall injuries as a result of blood pressure
medication in older people [31]. Evidence for lifestyle
management in older adults was brief in most CPGs, with
generally no information provided on the specific benefits
or effects on CVD or other outcomes for older people, the
amount of lifestyle change needed to benefit, or differ-
ences between age groups. None of the guidelines made
recommendations about when treatment could or should
be stopped. Use of medication to prevent CVD in older
people should be carefully monitored as the benefit-harm
trade-off may change if people, for example, become in-
creasingly frail [45].
Although the majority of the included CPGs provided
one or more statements describing under which circum-
stances the CPG might be difficult to implement for older
people, addressing issues such as lack of validation of the
risk models, increased risk side of effects, and the need to
adjust treatment targets, recommendations are varied and
brief. Given the heterogeneity of the older population, and
widely varying treatment (outcome) preferences, treatment
decision making needs to be tailored to the specific cir-
cumstances of the individual older adult, taking into
account their preferences and values [4, 20]. Half of the
CPGs recommended clinicians to apply the CPGs with
consideration of individual older patient context (e.g. co-
morbidities, life expectancy), but did not offer specific
guidance. Even fewer CPGs mentioned the importance of
older patient involvement in decision making and none of
the CPGs mentioned the importance of family members/
companions.
How our findings compare with other CPG assessments
Consistent with our findings, reviews of Canadian [37]
and Australian [36] CPGs on prevalent chronic condi-
tions in the older population found that although most
CPGs refer to the older population to some extent, only
a handful of them adequately address issues related to
older patients, especially patients with comorbidities.
One recent review of CPGs for patients with type-2 dia-
betes mellitus showed that the impact of multiple comor-
bidities, patient’s socio personal contexts, and patients’
personal values and preferences were only narrowly ad-
dressed in most CPGs [46]. Although this review did not
focus on older people specifically, it concurs with the lim-
ited attention to older patient context and patient involve-
ment the CPGs included in the current study, and
suggests it is an important issue with CPGs more broadly.
Limitations and strengths
The main limitation of our work is that we only looked at
statements specifically referring to older people and it
therefore does not allow for a comparison between recom-
mendations for older versus younger adults. It also means
that we did not include statements related to comorbidities
or frailty that may have been applicable to older people, if
they did not specifically address this group. However, we
know from previous studies that CPGs rarely consider pa-
tients with comorbidities [36, 37, 46] so it is unlikely that
including more general statements would have changed
our results. Moreover, from the viewpoint of a clinician
having to decide about the management of an older pa-
tient, guidelines would need to be clearly signposted as
relevant for older people rather than requiring extraction
from general text about management. Since our main ob-
jective was to examine the extent to which CVD CPGs ad-
dress older adults, we did not carry out a formal quality
evaluation of the CPGs. We limited our eligibility criteria
to CPGs published in English.
Finally, we did not include the recently published JBS3
[47], NICE CG181 [48] and NHLBI JNC8 CPG [49] in the
review as these were published after our last search date
(31 December 2013). However, these CPGs appear to have
a similar pattern to our main findings, with the exception
of NICE CG181. In both the JBS3 and JNC8 guidelines,
the discussion of older people is mainly limited to a rec-
ommendation to adjust treatment targets and/or
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thresholds The JBS8 has added an adjusted treatment
threshold for people aged ≥80 years (BP <150/90 mm Hg,
or <150/85 mm Hg if ambulatory or home BP monitoring
is used). JNC8 now recommends an adjusted treatment
threshold and target for people aged ≥60 years (SBP of
150 mmHg or DBP of 90 mmHg). Interestingly, the sec-
tion on hypertension in older people in JNC7 guideline
was removed in the JNC8 update. The updated NICE
CG181 guideline provides much more extensive discus-
sion of CVD risk management in older people than the
previous version (CG67) [39]. In CG67 the main recom-
mendation for older people had been to use clinical judge-
ment to assess risk in people aged 75 or older but that this
group could be considered at increased risk of CVD and is
likely to benefit from statin treatment. In CG181 the
major change is to explicitly recommend using the
QRISK2 risk assessment, which has been validated in
people up to, and including age 84 years. People aged 85
or older are considered to be at increased risk of CVD be-
cause of age alone and the CPG recommends considering
statin treatment in this group. However, detail is added to
make it explicit that there is limited evidence in older age
groups, that the benefit may only be in reduced non-fatal
MI and that consideration of risk and benefits and factors
such as polypharmacy, comorbidity, frailty and life expect-
ancy and informed patient preference are particularly im-
portant. It is also pointed out that there is a need for more
research on the effectiveness of statin therapy in older
people. The main strengths of our work includes the sys-
tematic approach, the use of a literature based data extrac-
tion method and the rigor of our analysis by employing
double coding of CPG selection and data extraction.
Implications for CPG development and research
Clinical practice guidelines set out a template for best prac-
tice for patient management to guide and support clinicians
in their care of patients. It is clear from our review that even
though clinicians report wanting additional advice about car-
ing for older patients, the current CPGs fail to provide ad-
equate guidance in the vast majority of cases. There is a
clear need for randomized trials on primary CVD prevention
in older people (with inclusion of the frail older person with
comorbidities) measuring outcomes that are meaningful to
older people, to enable evidence based decision making for
this group. At the same time, our results show that the ma-
jority of the CPGs do not even report the evidence that is
available [27, 28, 31–34], rendering it almost impossible for
older patients and their clinicians to make an informed deci-
sion about whether and how to manage CVD risk. CPG de-
velopers should think about ways to present available
evidence for older people in the CPGs or at least to highlight
the uncertainty around the evidence for this group. CPGs
should be structured so that they may be easily adapted to
older people with comorbidities, clearly present potential
benefits and harms to allow for comparison, and are condu-
cive to shared decision making. This may require the use of
new technology [50]. Existing guidance on risk communica-
tion [51] (although mainly limited to younger people), use of
prognostic indices [12] and health outcome prioritization
tools [13, 15] for decision making in older people could help
inform this process.
Conclusion
This study shows that only few primary CVD prevention
CPGs adequately address important issues common in the
care of older people. Given the changing demographics
and aging population worldwide, this is of major signifi-
cance. Future CPGs should provide more detailed evi-
dence and guidance on the management of older people
with multiple comorbidities and frailty, to ensure that dis-
cussions about the risk and benefits (and uncertainties) of
different management options can take place and clinician
and patients can make a shared decision that is tailored to
the individual patient’s circumstances and preferences.
CPGs must be designed to provide the best possible advice
and support to clinicians for the care of their patients.
Care of older patients will not improve until important as-
pects of their care are addressed by health care providers.
Achieving high quality guidelines to support clinicians is
an essential part of this process.
Additional files
Additional file 1: Appendix A. Overview CPG recommendations older
people (n=47), organised by medical condition then by year of
publication (reverse chronological) (PDF 354 kb)
Additional file 2: Appendix B. Examples of brief and more extensive
guideline recommendations for older people according to the three
criteria for CPG recommendations older people. (PDF 525 kb)
Additional file 3: Appendix C. Supporting Quotes from the CPGs (PDF
436 kb)
Abbreviations
AR: Absolute risk; CPG: Clinical Practice Guideline; CVD: Cardiovascular
Disease; DBP: Diastolic blood pressure; SBP: Systolic blood pressure.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
All the authors included in the paper fulfil the criteria of authorship. JJ
contributed to study design, analysis, interpretation, drafting, and revising
the manuscript. SM contributed to data collection, analysis, interpretation,
and revising the manuscript. CB contributed to analysis, interpretation, and
revising the manuscript. LI, JD, PG, BVM and KM contributed to study design,
interpretation, and revising the manuscript. BN contributed to data
collection, interpretation, and revising the manuscript. All authors approved
the final version of the manuscript and all authors are guarantors.
Acknowledgements
The authors would like to thank Ruth Mitchell for her help with the literature
search. The study was funded by a Program Grant awarded to the Screening
and Test Evaluation Program (STEP; 633003) from the National Health and
Jansen et al. BMC Family Practice  (2015) 16:104 Page 11 of 13
Medical Research Council (NHMRC). CB was supported by an Australian
Postgraduate Award. JJ (1037028) and KM (1029241) were supported by
NHMRC fellowships. Jenny Doust was supported by the NHMRC project
grant 511217. The funders had no role in the design or conduct of the
study; in the collection, analysis, and interpretation of the data; or in the
preparation or approval of the manuscript.
Author details
1Screening & Test Evaluation Program (STEP), Sydney School of Public Health,
The University of Sydney, Edward Ford Building A27, Sydney NSW 2006,
Australia. 2Centre for Medical Psychology and Evidence-based
Decision-making (CeMPED), The University of Sydney, Edward Ford Building
A27, Sydney NSW 2006, Australia. 3Faculty of Health Sciences and Medicine,
Bond University, Robina QLD 4226, Australia. 4Academic Medical Centre,
Department of Internal Medicine, University of Amsterdam, Meibergdreef 9,
1105 AZ Amsterdam, Netherlands. 5Department of Geriatrics, Gelre Hospitaal,
Albert Schweitzerlaan 31, 7334 DZ Apeldoorn, Netherlands.
Received: 10 February 2015 Accepted: 22 July 2015
References
1. Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice
guidelines and quality of care for older patients with multiple comorbid
diseases: implications for pay for performance. Jama. 2005;294:716–24.
2. Scott IA, Guyatt GH. Cautionary tales in the interpretation of clinical studies
involving older persons. Arch Intern Med. 2010;170:587–95.
3. Nair BR. Evidence based medicine for older people: available, accessible,
acceptable, adaptable? Australas J Ageing. 2002;21:58–60.
4. American Geriatrics Society. Expert Panel on the Care of Older Adults with
Multimorbidity. Patient-centered care for older adults with multiple chronic
conditions: a stepwise approach from the American Geriatrics Society. J Am
Geriatr Soc. 2012;60:1957–68.
5. Islam MM, Valderas JM, Yen L, Dawda P, Jowsey T, McRae IS. Multimorbidity
and comorbidity of chronic diseases among the senior Australians:
prevalence and patterns. PLoS One. 2014;9, e83783.
6. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology
of multimorbidity and implications for health care, research, and medical
education: a cross-sectional study. Lancet. 2012;380:37–43.
7. National Seniors Productive Ageing Centre. Senior Australians and
prescription medicines: usage, sources of information and affordability.
Canberra: Department of Health and Ageing; 2012.
8. National Center for Health Statistics. Health, United States: 2013: With Special
Feature on Prescription Drugs. Hyattsville, MD: U.S. Department of Health and
Human Services; 2014.
9. Gnjidic D, Hilmer SN, Blyth FM, Naganathan V, Waite L, Seibel MJ, et al.
Polypharmacy cutoff and outcomes: five or more medicines were used to
identify community-dwelling older men at risk of different adverse
outcomes. J Clin Epidemiol. 2012;65:989–95.
10. Tinetti ME, Bogardus Jr ST, Agostini JV. Potential pitfalls of disease-specific
guidelines for patients with multiple conditions. N Engl J Med. 2004;351:2870–4.
11. Holmes HM, Hayley DC, Alexander GC, Sachs GA. Reconsidering medication
appropriateness for patients late in life. Arch Intern Med. 2006;166:605–9.
12. Yourman LC, Lee SJ, Schonberg MA, Widera EW, Smith AK. Prognostic
indices for older adults: A systematic review. JAMA. 2012;307:182–92.
13. Fried TR, Tinetti ME, Iannone L, O'Leary JR, Towle V, Van Ness PH. Health
outcome prioritization as a tool for decision making among older persons
with multiple chronic conditions. Arch Intern Med. 2011;171:1854–6.
14. Fried TR, McGraw S, Agostini JV, Tinetti ME. Views of older persons with
multiple morbidities on competing outcomes and clinical decision‐making.
J Am Geriatr Soc. 2008;56:1839–44.
15. Tinetti ME, McAvay GJ, Fried TR, Allore HG, Salmon JC, Foody JM, et al.
Health outcome priorities among competing cardiovascular, fall injury, and
medication‐related symptom outcomes. J Am Geriatr Soc. 2008;56:1409–16.
16. Fried TR, O’Leary J, Van Ness P, Fraenkel L. Inconsistency over time in the
preferences of older persons with advanced illness for life-sustaining
treatment. J Am Geriatr Soc. 2007;55:1007–14.
17. Chewning B, Bylund CL, Shah B, Arora NK, Gueguen JA, Makoul G. Patient
preferences for shared decisions: a systematic review. Patient Educ Couns.
2012;86:9–18.
18. Arora NK, McHorney CA. Patient preferences for medical decision making:
who really wants to participate? Med Care. 2000;38:335–41.
19. Laidsaar-Powell RC, Butow PN, Bu S, Charles C, Gafni A, Lam WWT, et al.
Physician–patient–companion communication and decision-making: A
systematic review of triadic medical consultations. Patient Educ Couns.
2013;91:3–13.
20. van der Weijden T, Pieterse AH, Koelewijn-van Loon MS, Knaapen L, Légaré
F, Boivin A, et al. How can clinical practice guidelines be adapted to
facilitate shared decision making? A qualitative key-informant study. BMJ
Quality & Safety. 2013;22:855–63.
21. Petersen LK, Christensen K, Kragstrup J. Lipid-lowering treatment to the
end? A review of observational studies and RCTs on cholesterol and
mortality in 80 + −year olds. Age Ageing. 2010;39:674–80.
22. Gu Q, Burt VL, Dillon CF, Yoon S. Trends in antihypertensive medication use
and blood pressure control among United States adults with hypertension.
The National Health and Nutrition Examination Survey, 2001 to 2010.
Circulation. 2012;126:2105–14.
23. Ferket BS, Colkesen EB, Visser JJ, Spronk S, Kraaijenhagen RA, Steyerberg EW,
et al. Systematic review of guidelines on cardiovascular risk assessment:
which recommendations should clinicians follow for a cardiovascular health
check? Arch Intern Med. 2010;170:27–40.
24. D’Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al.
General cardiovascular risk profile for use in primary care the Framingham
Heart Study. Circulation. 2008;117:743–53.
25. Jackson R. Cardiovascular risk prediction: are we there yet? Heart. 2008;94:1–3.
26. Liew SM, Jackson R, Mant D, Glasziou P. Should identical CVD risks in young
and old patients be managed identically? Results from two models. BMJ
Open. 2012;2, e000728.
27. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al.
Treatment of hypertension in patients 80 years of age or older. N Engl J
Med. 2008;358:1887–98.
28. Beckett N, Peters R, Tuomilehto J, Swift C, Sever P, Potter J, et al. Immediate
and late benefits of treating very elderly people with hypertension: results
from active treatment extension to hypertension in the very elderly
randomised controlled trial. BMJ. 2012;344:d7541.
29. Baigent C, Keech A. Kearney PMa, Blackwell L, Buck G, Pollicino C, Kirby A,
Sourjina T, Peto R, Collins R, Cholesterol Treatment Trialists’(CTT)
Collaborators. Efficacy and safety of cholesterol-lowering treatment:
prospective meta-analysis of data from 90,056 participants in 14
randomised trials of statins. Lancet. 2005;366:1267–78.
30. Savarese G, Gotto Jr AM, Paolillo S, D’Amore C, Losco T, Musella F, et al.
Benefits of statins in elderly subjects without established cardiovascular
disease: a meta-analysis. J Am Coll Cardiol. 2013;62:2090–9.
31. Tinetti ME, Han L, McAvay GJ, Lee DSH, Peduzzi P, Dodson JA, et al.
Anti-hypertensive medications and cardiovascular events in older adults
with multiple chronic conditions. PLoS One. 2014;9, e90733.
32. Hilmer SG, Gnjidic D. Statins in older adults. Aust Prescr. 2013;36:79–82.
33. Naganathan V. Cardiovascular drugs in older people. Aust Prescr. 2013;36:190–4.
34. Butt DA, Mamdani M, Austin PC, Tu K, Gomes T, Glazier RH. The risk of falls
on initiation of antihypertensive drugs in the elderly. Osteoporos Int.
2013;24:2649–57.
35. Weiner M, Wells S, Kerse N. Perspectives of general practitioners towards
evaluation and treatment of cardiovascular disease among older people.
J Primary Health Care. 2009;1:198–206.
36. Vitry AI, Zhang Y. Quality of Australian clinical guidelines and relevance to
the care of older people with multiple comorbid conditions. Med J Aust.
2008;189:360–5.
37. Mutasingwa DR, Ge H, Upshur REG. How applicable are clinical practice
guidelines to elderly patients with comorbidities? Can Fam Physician.
2011;57:e253–62.
38. Moschetti I, Brandt D, Perera R, Clarke M, Heneghan C. Adequacy of
reporting monitoring regimens of risk factors for cardiovascular disease in
clinical guidelines: systematic review. BMJ. 2011;342:d1289.
39. National Institute for Health and Clinical Excellence. NICE Clinical Guideline
67: Lipid modification - Cardiovascular risk assessment and the modification
of blood lipids for the primary and secondary prevention of cardiovascular
disease. London: National Institute for Health and Clinical Excellence; 2010.
40. The Task Force for the Management of Arterial Hypertension of the
European Society of Hypertension and of the European Society of
Cardiology. 2007 Guidelines for the management of arterial hypertension.
Eur Heart J. 2007;28:1462–536.
Jansen et al. BMC Family Practice  (2015) 16:104 Page 12 of 13
41. Rothwell PM, Price JF, Fowkes FGR, Zanchetti A, Roncaglioni MC, Tognoni G,
et al. Short-term effects of daily aspirin on cancer incidence, mortality, and
non-vascular death: analysis of the time course of risks and benefits in 51
randomised controlled trials. Lancet. 2012;379:1602–12.
42. National Institute for Health and Clinical Excellence. NICE Clinical Guideline
127: Hypertension. Clinical management of primary hypertension in adults.
London: National Institute for Health and Clinical Excellence; 2011.
43. McMillan GJ, Hubbard RE. Frailty in older inpatients: what physicians need
to know. QJM. 2012;105:1059–65.
44. Fried TR, Tinetti ME, Towle V, O’Leary JR, Iannone L. Effects of benefits and
harms on older persons’ willingness to take medication for primary
cardiovascular prevention. Arch Intern Med. 2011;171:923–8.
45. Garfinkel D, Mangin D. Feasibility study of a systematic approach for
discontinuation of multiple medications in older adults: addressing
polypharmacy. Arch Intern Med. 2010;170:1648–54.
46. Wyatt KD, Stuart LM, Brito JP, Carranza Leon B, Domecq JP, Prutsky GJ,
et al. Out of context: clinical practice guidelines and patients with
multiple chronic conditions: a systematic review. Med Care. 2014;52
Suppl 3:S92–s100.
47. JBS3 Board. Joint British Societies’ consensus recommendations for the
prevention of cardiovascular disease (JBS3). Heart. 2014;100:ii1–ii67.
48. National Institute for Health and Care Excellence. NICE Clinical Guideline
CG181:Lipid modification: Cardiovascular risk assessment and the
modification of blood lipids for the primary and secondary prevention of
cardiovascular disease. London: National Institute for Health and Care
Excellence; 2014.
49. James PA, Oparil S, Carter B, Cushman W, Dennison-Himmelfarb C, Handler
J, et al. 2014 Evidence-based guideline for the management of high blood
pressure in Adults. Report from the panel members appointed to the
Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–20.
50. Guthrie B, Payne K, Alderson P, McMurdo MET, Mercer SW. Adapting clinical
guidelines to take account of multimorbidity. BMJ. 2012;345, e6341.
51. Trevena LJ, Zikmund-Fisher BJ, Edwards A, Gaissmaier W, Galesic M, Han PKJ,
et al. Presenting quantitative information about decision outcomes: a risk
communication primer for patient decision aid developers. BMC Med
Inform Decis Mak. 2013;13:S7.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Jansen et al. BMC Family Practice  (2015) 16:104 Page 13 of 13
